JP2024520307A5 - - Google Patents
Info
- Publication number
- JP2024520307A5 JP2024520307A5 JP2023570225A JP2023570225A JP2024520307A5 JP 2024520307 A5 JP2024520307 A5 JP 2024520307A5 JP 2023570225 A JP2023570225 A JP 2023570225A JP 2023570225 A JP2023570225 A JP 2023570225A JP 2024520307 A5 JP2024520307 A5 JP 2024520307A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- administration unit
- pharmaceutical
- pharmaceutical composition
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175623.4 | 2021-05-25 | ||
| EP21175623 | 2021-05-25 | ||
| PCT/EP2022/063887 WO2022248401A1 (en) | 2021-05-25 | 2022-05-23 | A plurality of tasquinimod particles and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520307A JP2024520307A (ja) | 2024-05-24 |
| JP2024520307A5 true JP2024520307A5 (enExample) | 2025-05-21 |
| JP7874664B2 JP7874664B2 (ja) | 2026-06-16 |
Family
ID=76098832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570225A Active JP7874664B2 (ja) | 2021-05-25 | 2022-05-23 | 複数のタスキニモド粒子およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12485095B2 (enExample) |
| EP (1) | EP4346773B1 (enExample) |
| JP (1) | JP7874664B2 (enExample) |
| KR (1) | KR20240012436A (enExample) |
| CN (1) | CN117295492A (enExample) |
| AU (1) | AU2022281056A1 (enExample) |
| BR (1) | BR112023023715A2 (enExample) |
| CA (1) | CA3218977A1 (enExample) |
| ES (1) | ES3048983T3 (enExample) |
| IL (1) | IL308542A (enExample) |
| MX (1) | MX2023013301A (enExample) |
| PL (1) | PL4346773T3 (enExample) |
| WO (1) | WO2022248401A1 (enExample) |
| ZA (1) | ZA202311594B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
| WO2012004338A1 (en) | 2010-07-09 | 2012-01-12 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2015160696A1 (en) | 2014-04-14 | 2015-10-22 | Yale University | Compositions and methods of inhibiting histone deacetylases |
| EP3041472B1 (en) | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
| BR112017009854B1 (pt) * | 2014-11-19 | 2022-08-23 | Active Biotech Ab | Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| WO2018208993A1 (en) * | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
-
2022
- 2022-05-23 KR KR1020237042849A patent/KR20240012436A/ko active Pending
- 2022-05-23 WO PCT/EP2022/063887 patent/WO2022248401A1/en not_active Ceased
- 2022-05-23 PL PL22730773.3T patent/PL4346773T3/pl unknown
- 2022-05-23 US US18/289,738 patent/US12485095B2/en active Active
- 2022-05-23 AU AU2022281056A patent/AU2022281056A1/en active Pending
- 2022-05-23 ES ES22730773T patent/ES3048983T3/es active Active
- 2022-05-23 CN CN202280034543.8A patent/CN117295492A/zh active Pending
- 2022-05-23 JP JP2023570225A patent/JP7874664B2/ja active Active
- 2022-05-23 EP EP22730773.3A patent/EP4346773B1/en active Active
- 2022-05-23 CA CA3218977A patent/CA3218977A1/en active Pending
- 2022-05-23 BR BR112023023715A patent/BR112023023715A2/pt unknown
- 2022-05-23 MX MX2023013301A patent/MX2023013301A/es unknown
- 2022-05-23 IL IL308542A patent/IL308542A/en unknown
-
2023
- 2023-12-18 ZA ZA2023/11594A patent/ZA202311594B/en unknown
-
2025
- 2025-11-24 US US19/399,224 patent/US20260076908A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060813A5 (enExample) | ||
| JP6757959B2 (ja) | 抗がん剤 | |
| TWI841481B (zh) | 乳酸鈣組成物及使用方法 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2003533485A5 (enExample) | ||
| CN105705148A (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| JP2019509253A5 (enExample) | ||
| WO2015187194A1 (en) | Use of paclitaxel particles | |
| JP2012522837A5 (enExample) | ||
| JP2019510785A5 (enExample) | ||
| JP2023546362A5 (enExample) | ||
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
| JP2022502450A5 (enExample) | ||
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| JP2021505669A5 (enExample) | ||
| JP2010504307A5 (enExample) | ||
| JP2024522163A5 (enExample) | ||
| JP2024524158A5 (enExample) | ||
| CA2925960A1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| WO2021185356A1 (zh) | 丁基苯酞及其衍生物的用途 | |
| CN111787922A (zh) | 用于治疗肝细胞癌的组合疗法 | |
| KR20140144213A (ko) | 3제를 조합한 신규 항종양제 |